Cargando…

Hypomethylating Agents for Treatment of Elderly Patients with Refractory Acute Myeloid Leukemia - A Case Report with a Focused Review of Literature

The prognosis of elderly patients with acute myeloid leukemia (AML) is poor. Intensive chemotherapy with the combination of cytarabine and anthracyclines is typically used as the first-line treatment in the elderly with newly diagnosed AML who are able to tolerate this regimen. Unfortunately, many p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tenneti, Pavan, Nagaiah, Govardhanan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6075624/ https://www.ncbi.nlm.nih.gov/pubmed/30087810 http://dx.doi.org/10.7759/cureus.2734

Ejemplares similares

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism
por: Zhao, Guangjie, et al.
Publicado: (2021)

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia
por: Delmas, Audrey, et al.
Publicado: (2023)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia
por: Ciotti, Giulia, et al.
Publicado: (2022)

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens
por: Maiti, Abhishek, et al.
Publicado: (2020)

Role of High-dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Ewing's Sarcoma: A Case Report with Focused Review of Literature
por: Tenneti, Pavan, et al.
Publicado: (2018)

Venetoclax + hypomethylating agents combined with dose-adjusted HAG for relapsed/refractory acute myeloid leukemia: Two case reports
por: Wang, Hongxia, et al.
Publicado: (2020)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
por: Mustafa Ali, Moaath K., et al.
Publicado: (2022)

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
por: Lee, Aaron M., et al.
Publicado: (2022)

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
por: Gbolahan, Olumide Babajide, et al.
Publicado: (2017)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Venetoclax combination therapy with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukaemia
por: Báez-Gutiérrez, Nerea, et al.
Publicado: (2021)

Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
por: Caiado, Francisco, et al.
Publicado: (2019)

Cardiac events in patients with acute myeloid leukemia treated with venetoclax combined with hypomethylating agents
por: Johnson, Isla M., et al.
Publicado: (2022)

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

P577: EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX
por: Zhang, Jian, et al.
Publicado: (2023)

Venetoclax Combined with Hypomethylating Agents for Treatment-Naïve B/Myeloid Mixed Phenotype Acute Leukemia
por: Wu, Di, et al.
Publicado: (2021)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
por: Gangat, Naseema, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

PB1900: COMBINED TREATMENT WITH VENETOCLAX PLUS HYPOMETHYLATING AGENT OR CYTARABINE VERSUS TREATMENT WITH HYPOMETHYLATING AGENT ALONE IN ACUTE MYELOID LEUKEMIA IN POOR PROGNOSIS PATIENTS.
por: Saavedra, Minerva Montalvo, et al.
Publicado: (2023)

P1738: A SEER-MEDICARE ANALYSIS OF THE ECONOMIC BURDEN AMONG ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS
por: McBride, A., et al.
Publicado: (2022)

Targeting the Immune Microenvironment in Acute Myeloid Leukemia: A Focus on T Cell Immunity
por: Lamble, Adam J., et al.
Publicado: (2018)

Extramedullary Acute Myeloid Leukemia: Leukemic Pleural Effusion, Case Report and Review of the Literature
por: Pemmaraju, Naveen, et al.
Publicado: (2014)

Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter
por: Kordella, Chryssoula, et al.
Publicado: (2021)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
por: Boddu, Prajwal, et al.
Publicado: (2018)

Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
por: Ferrara, Felicetto
Publicado: (2020)

Author Correction: Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection
por: Caiado, Francisco, et al.
Publicado: (2019)

Perspectives of caregivers of older adults with acute myeloid leukemia during initial hypomethylating agents and venetoclax chemotherapy
por: Tan, Kelly R., et al.
Publicado: (2023)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
por: Gangat, Naseema, et al.
Publicado: (2023)

Repeated Lineage Switches in an Elderly Case of Refractory B-Cell Acute Lymphoblastic Leukemia With MLL Gene Amplification: A Case Report and Literature Review
por: Takeda, Reina, et al.
Publicado: (2022)

Phase I Trial of Lithium and Tretinoin for Treatment of Relapsed and Refractory Non-promyelocytic Acute Myeloid Leukemia
por: Ueda, Masumi, et al.
Publicado: (2020)

Real‐life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory/relapsed: A single‐centre experience
por: Roldán Pérez, Alicia, et al.
Publicado: (2022)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f8e3onjqsl2fmfska5pcfhdo0v